A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Pembrolizumab (Primary) ; SEphB4-HSA (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- 21 Mar 2017 Planned End Date changed from 1 Jun 2020 to 21 Nov 2020.
- 21 Mar 2017 Planned primary completion date changed from 1 Jun 2019 to 21 Nov 2019.
- 21 Mar 2017 Status changed from not yet recruiting to recruiting.